Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial

Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial
Boulder, Colorado-based Accera has completed enrollment for its Phase 3 NOURISH AD clinical trial of AC-1204 for the treatment of mild to moderate Alzheimer’s disease (AD). Top-line data should be reported later this year. AC-1204 is an orally administered therapy with the potential to improve dementia patients’ cognition and daily functioning. The treatment works by inducing a

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *